Keith T. Flaherty to give talk at Protein Kinases meeting May 27-28, Boston
MONROVIA, CA â€' Keith T. Flaherty, Director of Developmental Therapeutics at Massachusetts General Hospital, Cancer Center to speak at GTCbioâ€™s 5th Protein Kinases in Drug Discovery conference May 27-28, 2010 in Boston, MA.
Keith T. Flaherty will give a presentation on â€śBRAF: the First Mutated Cytoplasmic Signaling Molecule to be Successfully Targeted in Cancerâ€ť. BRAF targeted therapy provides a new paradigm for matching therapy to somatic genetic changes identified prior to the initiation of therapy. NRAS mutations are known to occur in an additional 20% of melanomas, but represent a unique therapeutic challenge. Additional genetic discoveries may provide a basis of combinations of targeted therapy, in an effort to extend the early success of BRAF inhibitors in the subpopulations bearing mutations in these oncogenes. Updated data from the phase I/II trial will be presented.
Dr. Flaherty received a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. He trained in internal medicine at Brigham and Womenâ€™s Hospital and completed a fellowship in medical oncology at the University of Pennsylvania. He joined the faculty in the School of Medicine at the University of Pennsylvania as an Assistant Professor of Medicine and member of the Developmental Therapeutics Program in the Abramson Cancer Center in 2002. In 2009, he moved to the Massachusetts General Hospital Cancer Center to lead the Developmental Therapeutics Program.
Dr. Flaherty is the principal investigator of numerous first-in-human clinical trials with novel targeted therapies, and is the principal investigator of two national, cooperative group trials: E2603, a phase III trial comparing sorafenib, carboplatin and paclitaxel to carboplatin and paclitaxel alone in patients with metastatic melanoma and E2804, a randomized phase II trial comparing combinations of anti-angiogenic agents in metastatic renal cell carcinoma. Dr. Flaherty has led the clinical development of the first three Raf inhibitors, ultimately validating mutated BRAF as a therapeutic target in cancer. He is internationally known for expertise in clinical and translational research directed against signal transduction pathways in melanoma.
Dr. Flaherty currently maintains a clinical focus on melanoma and renal cell carcinoma, with an overall emphasis on developing novel therapies for these historically treatment-refractory malignancies.
Also presenting at the Protein Kinase conference are prestigious organizations including AstraZeneca, Bristol-Myers Squibb, Dana-Farber, Dartmouth, Genentech, GlaxoSmithKline, Harvard, Roche, Merck, Pfizer, Tufts, UCSD, Wyeth and other leaders in the kinase industry.
The 5th Protein Kinases in Drug Discovery targets & inhibitors in inflammatory disorders. For conference features presentations on new technology for kinase target and inhibitor identification and screening, kinase selectivity, kinase drug design, kinase targets & inhibitors in oncology, kinase targets & inhibitors in CNS disorders, and kinase more information, visit http://www.gtcbio.com.
User comments, Ratings and Reviews
[Bookmark & read later
/ Comment this story ]
GTCbio from 59.95.161.xxx
Article Taged as : keith, flaherty, give, talk, protein, kinases, meeting, 27-28,, boston, http, www.gtcbio.com, keith, flaherty, give, talk, protein, kinases, meeting, 27-28,, boston,
Article Viewed 3619 times.
Positive attitude 1 votes [0%]
Negetive attitude 1 votes [0%]
News Article Source & Groups
You can find this article under group.
And brought to you by Channel ,
The XMl Feed Type and collected data bytes sized news and still counting.
Feed Server name is and Code Page (Not Defined/Un Known)
: : Keith T. Flaherty to give talk at Protein Kinases meeting May 27-28, Boston
Date Listed : Tuesday, March 16, 2010
Source : ,
- Boston area Intellectual Property Firm Patents Etcetera Announces a.Patents Etcetera announces a novel fire-fighting device, the Grantham MechVent™, designed to minimize the possibility of flashover during a building fire.(PRWeb February 17, 2012)Read the full story at http://www.prweb.com/releases/firefighting/granthammechvent/prweb9189891.htm
- Neurodegenerative diseases Ring like structure found in elongator protein complex A ring-like structure found in a protein complex called Elongator' provides new clues to its tasks inside the cell and to its role in neurodegenerative diseases. It is the first ...
- Protein that sends painful touch signals identified Researchers report that they have identified a class of proteins that detect "painful touch." Scientists have known that sensory nerves in our skin detect pressure, pain, heat, cold, and other ...
- A single protein helps the body keep watch over the Epstein Barr virus Some 90 percent of people are exposed to the Epstein Barr virus at some point in their life. Even though it is quickly cleared from the body, the virus can ...
- Caltech scientists uncover structure of key protein in common HIV subgroup PASADENA, Calif. -- Scientists from the California Institute of Technology (Caltech) have provided the first-ever glimpse of the structure of a key protein -- gp120 -- found on the surface ...
- New method for producing proteins critical to medical research Scientists have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases. The chemical method yields hundreds-fold more ubiquitylated proteins than current approaches. Such ...
- Melamine in milk Tiny gold particles help researchers find protein impostorResearchers have developed a fast, economical and easy method to detect melamine in milk, using gold nanoparticles.
- Dangerous plaques in blood vessels rupture by overproducing protein busting enzymesSEATTLE -- University of Washington (UW) researchers have gathered evidence that dangerous plaques in blood vessels can rupture by overproducing protein-digesting enzymes. Plaques are fat-laden...
- Protein linked to problems with executive thinking skills New research shows that a high level of C-reactive protein (CRP), a marker for inflammation in the blood, is associated with brain changes that are linked to problems with executive ...
- CITES meeting rejects protection for marine species The Convention on International Trade in Endangered Species (CITES) meeting in Qatar rejected protection for marine species, including sharks, bluefin tuna, and coral, disappointing the US, environmentalists, and marine scientists.